Rhabdomyosarcoma Therapeutics Analysis 2018 by Key Players Roche, Epizyme, Novartis

RMS therapeutics pipeline currently exhibit a proliferating pipeline with 18 drug candidates.

RMS is a rare and malignant type of tumor which can arise from skeletal muscles, tendons, or connective tissues. The pathophysiology of this type of cancer is still unknown, but when it arises from the skeletal muscles, it can spread to any part of the body. RMS majorly arises from skeletal muscles, but the reason behind this remains unknown. RMS is the most common soft tissue tumor that occurs during childhood and accounts for approximately half of all soft tissue sarcomas in this age group.

Download report sample at: https://www.psmarketresearch.com/market-analysis/rms-therapeutics-pipeline-analysis/report-sample

*Advancement in Technology to Support RMS Therapeutics Pipeline Growth

Most of the companies are developing drug candidates using advanced technologies, and these drug candidates have showed positive efficacy in the clinical stage of development. For instance, Iproteos SL is developing its drug candidate using IPROTech technology platform which involves a combination of in-silico and in-vitro techniques. The technology encompasses state-of-the-art of various scientific fields, such as computational chemistry, modern organic synthesis, peptide chemistry, and experimental validation of potency, absorption, distribution, metabolism, and excretion (ADME) and permeability properties.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=rms-therapeutics-pipeline-analysis

Some of the key players involved in the development of RMS therapeutics include F. Hoffmann-La Roche Ltd., Epizyme Inc. and Novartis AG.

*RMS Therapeutics Pipeline is Witnessing Significant Growth due to Development of Combination Therapies

Several companies are developing combination therapies for the treatment of RMS, as these therapies are cost-effective and improve medication compliance by reducing burden of pills. For instance, (Dasatinib + Ganitumab) is a combination therapy under the Phase II stage of development by Bristol-Myers Squibb Company for the treatment of RMS. The drug candidate is a combination of small molecule (dasatinib) and monoclonal antibody (ganitumab), obtained from synthetic and natural source, respectively. It acts as Bcr-abl tyrosine kinase inhibitor and EphA2 receptor antagonist (dasatinib); and insulin-like growth factor-I receptor antagonist (ganitumab).

Browse report at: https://www.psmarketresearch.com/market-analysis/rms-therapeutics-pipeline-analysis

Combination therapies help to reduce frequency of dose administration, increase synergistic effect, and increase the potency of drugs for the treatment of RMS, thus driving the growth in pipeline.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.